Search
Coeptis Therapeutics Holdings Inc
COEPAdd to Watchlist
16.400USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
579.55MMarket Cap
LossP/E TTM
More Details of Coeptis Therapeutics Holdings Inc Company
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Coeptis Therapeutics Holdings Inc Info
Ticker SymbolCOEP
Company nameCoeptis Therapeutics Holdings Inc
IPO dateDec 17, 2020
CEOMehalick (David)
Number of employees5
Security typeOrdinary Share
Fiscal year-endDec 17
Address105 Bradford Road, Suite 420
CityWEXFORD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code15090
Phone17249346467
Websitehttps://coeptistx.com/
Ticker SymbolCOEP
IPO dateDec 17, 2020
CEOMehalick (David)
Company Executives of Coeptis Therapeutics Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
330.19K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
70.53K
-7.09%
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
64.03K
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
22.50K
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
8.95K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
330.19K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
70.53K
-7.09%
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
64.03K
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
22.50K
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
8.95K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Coeptis Therapeutics Holdings Inc?
The top five shareholders of Coeptis Therapeutics Holdings Inc are: Mr. David Mehalick
How many institutions hold shares of Coeptis Therapeutics Holdings Inc (COEP)?
As of 2026Q1, 41 institutions hold shares of Coeptis Therapeutics Holdings Inc, with a combined market value of approximately 571.15K, accounting for 1.17% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 58739.00.